For instance, GSTP1 c313AG or GG was associated with an increased risk of moderate/severe hearing impairment in 106 [41] and 64 children [43], respectively, treated with platinum agents, using the Brock hearing loss classification of equal or greater than 2 [20]. Here, GSTP1 is linked to Hearing impairment.